UNDERWRITING AGREEMENTUnderwriting Agreement • November 27th, 2024 • Curanex Pharmaceuticals Inc • Pharmaceutical preparations • New York
Curanex Pharmaceuticals Inc,, a corporation incorporated under the law of the State of Nevada (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Dominari Securities LLC, and with the other underwriters named on Schedule I hereto. (each an “Underwriter” and together, the “Underwriters”) an aggregate of [*] shares (the “Closing Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). No Closing Shares will be certificated. At the option of the Underwriters, the Company agrees, subject to the terms and conditions herein, to issue and sell additional Option Shares (as defined in Section 3(b) hereof). The Closing Shares and the Option Shares are herein referred to collectively as the “Securities.” The number of Closing Shares and Option Shares to be purchased by each Underwriter is set forth opposite its name in Schedule I hereto. Each of the Underwriters has agreed to act as underwriters in connecti
Amended and Restated Subscription AgreementSubscription Agreement • November 27th, 2024 • Curanex Pharmaceuticals Inc • Pharmaceutical preparations • Nevada
This Amended and Restated Subscription Agreement (the “Agreement”) is made effective as of November 27, 2024 by and between Curanex Pharmaceuticals Inc, a Nevada Corporation (the “Company”), and Xiaohong Song (the “Subscriber”).
